Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella.
The use of live attenuated invasive bacteria as a carrier for DNA-based vaccines has been reported recently. In this study, we used a Shigella flexneri serotype 2a rfbF mutant for immunization of a DNA vaccine coding for HIV-1 SF2 Gag. The recombinant bacterial vector delivered gag DNA to mammalian cells in vitro resulting in Gag protein expression, and was found to have a low level of pathogenicity among a number of Shigella cell spread defective mutants tested. Intranasal immunization of mice with live recombinant bacterial cells induced a gag-specific cellular immune response similar to that seen with i.m. injection of naked DNA. Importantly, a strong boosting effect was observed in mice primed with DNA, suggesting utility of bacterial vectors in prime-boost vaccination regimens.
Xu
Fengfeng
F
Vaccines Research, Chiron Corporation, 4560 Horton St, mail stop 4-3, Emeryville, CA 94608, USA.
Hong
Mei
M
Ulmer
Jeffrey B
JB
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D005260:Female; D015683:Gene Products, gag / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D007273:Injections, Intramuscular; D051379:Mice; D008815:Mice, Inbred Strains; D012763:Shigella flexneri / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*
D016915:AIDS Vaccines; D015683:Gene Products, gag; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA